Dec 31, 2025 • MarketBeat
BULLISH
VIRGINIA RETIREMENT SYSTEMS ET Al Has $49.07 Million Stake in IDEXX Laboratories, Inc. $IDXX
VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 29.5% in the third quarter, now holding 76,808 shares valued at $49.07 million. Analyst sentiment is generally positive, with a "Moderate Buy" rating and an average price target of $763.50. IDEXX Laboratories recently surpassed quarterly earnings estimates and provided optimistic FY2025 guidance.
Dec 31, 2025 • Simply Wall Street
BULLISH
Investors in IDEXX Laboratories (NASDAQ:IDXX) have seen respectable returns of 65% over the past year
IDEXX Laboratories (NASDAQ:IDXX) shareholders have experienced a 65% return over the past year, significantly outperforming the broader market. This strong stock performance is attributed to the company's 21% EPS growth, which has led to a favorable market sentiment reflected in a high P/E ratio. The article suggests that this positive momentum might indicate a good time for investors to further examine the company.
Dec 30, 2025 • Yahoo Finance
BULLISH
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
Zacks Equity Research highlights Veracyte (VCYT), IDEXX Laboratories (IDXX), and Intuitive Surgical (ISRG) as key players in the Medical Instruments industry. Despite macroeconomic headwinds and regulatory adjustments, these companies have adapted well, leveraging generative AI and M&A trends. The industry outlook, however, remains subdued according to the Zacks Industry Rank, even as the global AI in healthcare market projects significant growth.
Dec 30, 2025 • Nasdaq
SOMEWHAT-BULLISH
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
The medical instruments industry is experiencing a transformative shift due to generative AI (genAI) and ongoing M&A trends, despite global economic slowdowns and supply chain issues. Companies like Veracyte, IDEXX Laboratories, and Intuitive Surgical are adapting well to these changes by leveraging innovative technologies and strategic initiatives, leading to an uptrend in their stock prices. The industry's near-term outlook remains challenging due to various economic headwinds, but individual companies with strong earnings potential are positioned for growth.
Dec 29, 2025 • Yahoo Finance Singapore
BULLISH
Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?
IDEXX Laboratories (IDXX) stock has outperformed its Medical sector peers this year, gaining 66.5% compared to the sector's average of 8.2%. The company, holding a Zacks Rank #2 (Buy), also shows strong analyst sentiment with a 2.5% increase in its full-year earnings estimate over the past 90 days. Artivion (AORT) is another medical stock demonstrating strong performance within the same industry group as IDEXX.
Dec 29, 2025 • MarketBeat
NEUTRAL
Three Seasons Wealth LLC Takes Position in IDEXX Laboratories, Inc. $IDXX
Three Seasons Wealth LLC has acquired a new stake of 5,126 shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during Q3, valued at approximately $3.28 million, making it their 20th largest holding. This comes as IDEXX reported strong Q3 earnings, beating analyst expectations with $3.22 EPS and $1.11 billion in revenue, and received several analyst price target upgrades. Despite an insider sale by EVP Nimrata Hunt, institutional investors hold a significant portion of the company's stock, and analysts maintain a "Moderate Buy" rating with a consensus target price of $763.50.